Last reviewed · How we verify
LY110140
At a glance
| Generic name | LY110140 |
|---|---|
| Also known as | Fluoxetine Hydrochloride, Prozac, Sarafem |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression (PHASE3)
- A Study in the Treatment of Children and Adolescents With Major Depressive Disorder (PHASE3)
- A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing (PHASE3)
- A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing (PHASE3)
- A Study of LY110140 in Healthy Japanese Male Participants (PHASE1)
- A Study in the Treatment of Children and Adolescents With Major Depressive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY110140 CI brief — competitive landscape report
- LY110140 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI